Envestnet Asset Management Inc. boosted its position in Fluor Co. (NYSE:FLR – Get Rating) by 1.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 109,136 shares of the construction company’s stock after buying an additional 1,187 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.08% of Fluor worth $2,716,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also bought and sold shares of FLR. Allworth Financial LP increased its position in Fluor by 70.9% in the third quarter. Allworth Financial LP now owns 1,080 shares of the construction company’s stock worth $27,000 after buying an additional 448 shares during the last quarter. Meeder Asset Management Inc. increased its position in Fluor by 91.7% in the second quarter. Meeder Asset Management Inc. now owns 1,403 shares of the construction company’s stock worth $34,000 after buying an additional 671 shares during the last quarter. Atlas Capital Advisors LLC increased its position in Fluor by 665.0% in the second quarter. Atlas Capital Advisors LLC now owns 1,836 shares of the construction company’s stock worth $45,000 after buying an additional 1,596 shares during the last quarter. Wipfli Financial Advisors LLC purchased a new stake in Fluor in the third quarter worth $77,000. Finally, SeaCrest Wealth Management LLC purchased a new stake in Fluor in the second quarter worth $92,000. 94.28% of the stock is owned by hedge funds and other institutional investors.
Fluor Price Performance
NYSE:FLR opened at $36.81 on Wednesday. The firm has a market capitalization of $5.24 billion, a price-to-earnings ratio of 50.42, a P/E/G ratio of 0.87 and a beta of 2.29. Fluor Co. has a 52-week low of $21.67 and a 52-week high of $38.20. The stock has a fifty day moving average of $35.75 and a 200 day moving average of $32.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.57 and a current ratio of 1.57.
Insider Activity at Fluor
In other Fluor news, insider James R. Breuer sold 4,000 shares of Fluor stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $37.81, for a total transaction of $151,240.00. Following the completion of the sale, the insider now owns 41,742 shares of the company’s stock, valued at $1,578,265.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.01% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on FLR shares. UBS Group lifted their price target on Fluor from $26.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, November 29th. Robert W. Baird lifted their price target on Fluor from $38.00 to $43.00 and gave the company an “outperform” rating in a research report on Wednesday, February 22nd. Finally, Credit Suisse Group lifted their price target on Fluor from $31.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, February 22nd. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Fluor currently has an average rating of “Hold” and an average price target of $35.29.
Fluor Company Profile
Fluor Corp. operates as a holding company. The firm engages in the provision of engineering, procurement, construction, fabrication and modularization, operations, maintenance and asset integrity, as well as project management services, on a global basis. It operates through the following segments: Energy & Chemicals, Mining & Industrial, Infrastructure & Power, Diversified Services and Government.
- Get a free copy of the StockNews.com research report on Fluor (FLR)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Fluor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluor and related companies with MarketBeat.com's FREE daily email newsletter.